⌕
ImmunityBio · IBRX · Nasdaq
Tenet 51 · Mixed
Compare
$6.70+7.03%At closeTenet 51 · Mixed
$6.70+0.44 (+7.03%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD

ImmunityBio (IBRX) Stock

ImmunityBio (IBRX) closed at $6.70 on Nov 18, 2026; its Tenet Score is 51 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

35 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$6.70
Nov 18, 2026
Market cap
$6.7B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
1.95 – 12.43
low → high · as of close, Nov 17, 2026
Tenet Score
51/100
Mixed · 340 Healthcare peers

Industry: Drugs

ImmunityBio Inc scores 51/100. Mixed. Strongest on financial health, quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 51 is built from 3 of 4 pillars, from 45% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
51/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
33
Health
69
Growth
52

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value omitted — no data yet.
Value—QualityDHealthCGrowthCMomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
58.8×
price to sales, fiscal 2025 · as of close, Nov 17, 2026
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
−226.0%
before interest and tax
Net margin
−310.2%
fiscal year to Dec 31, 2025
Current ratio
5.10
fiscal year to Dec 31, 2025
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators,…

Composite computed Nov 17, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 84 US ETFs · top wrappers by weightSee all ETFs holding IBRX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 17, 2026.

What sector and industry is ImmunityBio in?

ImmunityBio is in the Healthcare sector and the Drugs industry.

What is ImmunityBio's Tenet Score?

ImmunityBio's Tenet Score is 51 out of 100, ranked against 340 Healthcare peers as of Nov 17, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.